A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) with Plaque Psoriasis. J of Skin [Internet]. 2020 Sep. 2 [cited 2026 Apr. 30];4(5):s35. Available from: https://skin.dermsquared.com/skin/article/view/984